ArticleInternational journal for equity in health2020
Ease and equity of access to free DR-TB services in Nigeria- a qualitative analysis of policies, structures and processes.
Article in International journal for equity in health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Barriers That Interfere with Access to Tuberculosis Diagnosis and Treatment across Countries Globally: A Systematic Review.ACS infectious diseases · 2024Pooled it
- Epidemiological and clinical review of spinal Tuberculosis at a Regional Orthopaedic Hospital in Nigeria.International orthopaedics · 2026Article
- Barriers to the diagnosis and treatment of tuberculosis in Abidjan, Côte d'Ivoire: a qualitative study.BMC public health · 2026Article
- "Miss, I want itchy medicine": Understanding what, why, and how antibiotics are used in Central Java province, Indonesia through the drug bag method.PLOS global public health · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- A methodological review of patient healthcare-seeking journeys from symptom onset to receipt of care.BMJ global health · 2025Review
- The effects of stigma and social support on the health-related quality of life of people with drug resistance tuberculosis in Lagos, Nigeria.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- COVID-19 policies and tuberculosis services in private health sectors of India, Indonesia, and Nigeria.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management.Journal of multidisciplinary healthcare · 2025Review
- Age-period-cohort analysis and prediction of tuberculosis trends in China-based on the Global Burden of Disease 2021 data.Frontiers in public health · 2025Article
- Individual journeys to tuberculosis care in Nigeria's private sector during the COVID-19 pandemic.BMJ global health · 2024Article
- Social protection as a right of people affected by tuberculosis: a scoping review and conceptual framework.Infectious diseases of poverty · 2023Article
- Tuberculosis service disruptions and adaptations during the first year of the COVID-19 pandemic in the private health sector of two urban settings in Nigeria-A mixed methods study.PLOS global public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPersistent low rates of case notification and treatment coverage reflect that accessing diagnosis and treatment for drug-resistant tuberculosis (DR-TB) in Nigeria remains a challenge, even though it is provided free of charge to patients. Equity in health access requires availability of comparable, appropriate services to all, based on needs, and irrespective of socio-demographic characteristics. Our study aimed to identify the reasons for Nigeria's low rates of case-finding and treatment for DR-TB. To achieve this, we analyzed elements that facilitate or hinder equitable access for different groups of patients within the current health system to support DR-TB management in Nigeria.
methodsWe conducted documentary review of guidelines and workers manuals, as well as 57 qualitative interviews, including 10 focus group discussions, with a total of 127 participants, in Nigeria. Between August and November 2017, we interviewed patients who were on treatment, their treatment supporter, and providers in Ogun and Plateau States, as well as program managers in Benue and Abuja. We adapted and used Levesque's patient-centered access to care framework to analyze DR-TB policy documents and interview data.
resultsThematic analysis revealed inequitable access to DR-TB care for some patient socio-demographic groups. While patients were mostly treated equally at the facility level, some patients experienced more difficulty accessing care based on their gender, age, occupation, educational level and religion. Health system factors including positive provider attitudes and financial support provided to the patients facilitated equity and ease of access. However, limited coverage and the absence of patients' access rights protection and considerations in the treatment guidelines and workers manuals likely hampered access.
conclusionIn the context of Nigeria's low case-finding and treatment coverage, applying an equity of access framework was necessary to highlight gaps in care. Differing social contexts of patients adversely affected their access to DR-TB care. We identified several strengths in DR-TB care delivery, including the current financial support that should be sustained. Our findings highlight the need for government's commitment and continued interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.